Back to discover
Disease

Leukemia, Myeloid

Late-stage therapeutic developmentEmerging research
MeSHLeukemia, Myeloid
2
Publications
18
Clinical trials
12
Associated genes
5
Related proteins
2016
Latest publication
Current focus
Cytidine deaminase biologyTherapeutic developmentInflammation & immunity
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
Clinical Milestones4View
Results expected 2
Recently completed 1
Other updates 1
Activity timeline4

Clinical trials

16 sponsors · 1 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
16
Late-stage
6
Completed
Late-stage studies

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy

Phase 3 · Recruiting · Janssen Research & Development, LLC

Decitabine Plus mBU/CY for High Risk Acute Leukemia With Minimal Residual Disease Pre-HSCT

Phase 2/3 · Recruiting · Peking University People's Hospital

A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy

Phase 3 · Active, not recruiting · PETHEMA Foundation

A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase 3 · Active, not recruiting · Otsuka Australia Pharmaceutical Pty Ltd

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission

Phase 3 · Completed · Celgene

A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Phase 3 · Completed · Celgene
Recruiting

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy

Phase 3 · Recruiting · Janssen Research & Development, LLC

Decitabine Plus mBU/CY for High Risk Acute Leukemia With Minimal Residual Disease Pre-HSCT

Phase 2/3 · Recruiting · Peking University People's Hospital

A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 · Recruiting · Orca Biosystems, Inc.

A Multi-center, Prospective, Single-arm Study of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia (R/R AML)

Phase 2 · Recruiting · The First Affiliated Hospital of Xiamen University
Recently completed

A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA

Phase 3 · Completed · Pfizer

A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Phase 3 · Completed · Celgene

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission

Phase 3 · Completed · Celgene

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Phase 3 · Completed · Astex Pharmaceuticals, Inc.

A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy

Phase 2/3 · Completed · Janssen Research & Development, LLC

A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy

Phase 3 · Completed · Boehringer Ingelheim

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
19662016
Major themes3
  • Leukocyte Count1
  • Leukopenia1
  • Lymphocytes1
Leading journals2
  • Annals of internal medicine1
  • Blood1
Leading researchers8
  • Arber DA1
  • Bloomfield CD1
  • Bodey GP1
  • Borowitz MJ1
  • Buckley M1
  • Cazzola M1
  • Freireich EJ1
  • Hasserjian R1
Affiliations (unnormalised)6
  • Comprehensive Cancer Center1
  • Institute of Pathology1
  • John Hopkins Medical Institutions1
  • Massachusetts General Hospital1
  • Stanford University1
  • University of Chicago1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

DNMT3A0.68ASXL10.59SRSF20.59DDX410.56DNMT10.49IDH20.46CD330.40AXL0.40CDA0.39FREM30.31TIMP40.31GPR1490.29

Disease biology

5 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

DNA (cytosine-5)-methyltransferase 3Avia DNMT3A0.68DNA (cytosine-5)-methyltransferase 1via DNMT10.49Myeloid cell surface antigen CD33via CD330.40Tyrosine-protein kinase receptor UFOvia AXL0.40Cytidine deaminasevia CDA0.39

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.

Identifiers
MeSHLeukemia, Myeloid
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.